[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603773":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":69,"collaborators":25,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":25,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":25,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"University of Florida","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Zinc first","EXPERIMENTAL","Encapsulated zinc citrate 30 mg orally daily for 3 months followed by placebo capsule matching zinc daily for 3 months",[13,14],"Drug: Zinc citrate","Drug: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"Placebo first","Placebo capsule matching zinc daily for 3 months, followed by encapsulated zinc citrate 30 mg orally daily for 3 months",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Zinc citrate","Oral zinc citrate 30 mg daily",[16,9],null,{"type":21,"name":27,"description":27,"armGroupLabels":28,"otherNames":25},"Placebo",[16,9],[30],{"name":31,"affiliation":5,"role":32},"Lauren Fanty, MD","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Julie Segura, BA","CONTACT","352-733-2412","Julie.Segura@neurology.ufl.edu",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Norman Fixel Institute for Neurological Diseases","RECRUITING","Gainesville","Florida","32608","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-82.32483,29.65163,{"lat":52,"lon":51},[55,56,59,61,63,65,67],{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"name":57,"role":58,"phone":25,"phoneExt":25,"email":25},"Anastasia Barnes, MD","SUB_INVESTIGATOR",{"name":60,"role":58,"phone":25,"phoneExt":25,"email":25},"Jerry Fenn, MD, PhD",{"name":62,"role":58,"phone":25,"phoneExt":25,"email":25},"Pooja Gupta, MD",{"name":64,"role":58,"phone":25,"phoneExt":25,"email":25},"Matthew Remz, MD",{"name":66,"role":58,"phone":25,"phoneExt":25,"email":25},"Jun Yu, MD",{"name":68,"role":58,"phone":25,"phoneExt":25,"email":25},"Irene Malaty, MD",{"type":70,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100603773","phase-2-zinc-as-an-adjunctive-therapy-for-cervical-dystonia-100603773",false,"NCT07140874","Zinc as an Adjunctive Therapy for Cervical Dystonia","Evaluation of Supplemental Zinc as an Adjunct to Prolong the Duration of Benefit After Botulinum Toxin Injections in Subjects With Cervical Dystonia","Inclusion Criteria:\n\n* Adults aged 18-89 years.\n* Diagnosed with cervical dystonia.\n* Receiving regular BoNT type A (Botox) injections for at least six months.\n\nExclusion Criteria:\n\n* Known allergy or intolerance to zinc.\n* Significant comorbidities or concurrent medications that could interfere with study outcomes.\n* Pregnant or breastfeeding women.\n* Already taking a zinc supplement which would exceed tolerable upper intake level in adults (40 mg elemental zinc per day) with addition of zinc study supplement.","ALL","18 Years","89 Years",{"count":82,"type":83},25,"ESTIMATED","INTERVENTIONAL",[86],"PHASE2","The goal of this clinical trial is to evaluate if supplemental zinc can prolong the duration of benefit of botulinum toxin injections in cervical dystonia patients receiving care at the University of Florida.\n\nThe main aims are:\n\n1. To evaluate the efficacy of zinc citrate supplementation in prolonging the duration of symptom relief provided by botulinum toxin type A (Botox) injections in cervical dystonia patients.\n2. To assess the safety and tolerability of zinc supplementation in this patient population.\n3. To analyze the potential influence of zinc supplementation on the quality of life and functional outcomes in cervical dystonia patients receiving Botox.\n\nResearchers will compare zinc citrate to a placebo (a look-alike substance that contains no active drug) to see if zinc works to extend the effects of Botox.\n\nParticipants will:\n\nTake zinc citrate or a placebo every day for 3 months, then cross over to the alternative treatment for another 3 months.\n\nVisit the clinic every 3 months for Botox injections, check ups and surveys.",[89],"Cervical Dystonia",[91,92,93,94,95],"cervical dystonia","botulinum toxin","Botox","zinc citrate","zinc","2026-05-12",{"date":98,"type":99},"2026-05-15","ACTUAL",{"date":101,"type":83},"2026-06-01",{"date":103,"type":83},"2027-05-31",{"name":5,"class":6},1]